ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
WP2877	Vitamin D receptor pathway	18/185	143/5963	3.34645258657233e-07	8.6338476733566e-05	8.63032509168653e-05	604/820/634/78989/1543/1591/168002/1946/727936/9173/27035/6279/6280/219855/25928/79689/8600/54210	18
WP2848	Pluripotent stem cell differentiation pathway	6/185	34/5963	0.000535833524738067	0.0691225246912106	0.0690943229267507	3577/22943/2246/10637/7018/8600	6
WP1423	Ganglio sphingolipid metabolism	3/185	10/5963	0.0030013697660759	0.258117799882528	0.258012488662665	8708/30815/6489	3
WP3527	Pre-implantation embryo	5/185	35/5963	0.00414833401837555	0.267567544185223	0.267458377500529	366/1958/2354/4603/7004	5
WP5188	Retinol Metabolism	3/185	12/5963	0.00525604820547861	0.271212087402696	0.271101433756265	1543/10170/195814	3
WP24	Peptide GPCRs	5/185	41/5963	0.00824533544614845	0.335797070244118	0.335660066135491	3577/2358/4886/4887/5540	5
WP5083	Neuroinflammation and glutamatergic signaling	9/185	115/5963	0.00911077322367762	0.335797070244118	0.335660066135491	816/1610/2893/2904/2918/7850/6506/6513/92745	9
WP455	GPCRs, class A rhodopsin-like	9/185	118/5963	0.0107030510058637	0.345173394939105	0.345032565320607	1238/136/3577/2358/2852/3357/4886/4887/5540	9
WP2840	Hair follicle development: cytodifferentiation - part 3 of 3	6/185	65/5963	0.0149045377694996	0.427263416058987	0.427089093979812	22943/2354/8456/25928/11005/7704	6
WP5094	Orexin receptor pathway	8/185	112/5963	0.0225388250518198	0.581501686336952	0.581264435546933	655/1958/2354/2904/4314/6506/6513/114088	8
WP1533	Vitamin B12 metabolism	4/185	37/5963	0.0266614564654565	0.625332342553434	0.625077208998741	3043/6288/6289/6947	4
WP4917	Proximal tubule transport	4/185	42/5963	0.0401311231210693	0.855158332302239	0.854809430493874	760/762/6513/160728	4
WP3930	EDA signaling in hair follicle development	2/185	11/5963	0.043801724301643	0.855158332302239	0.854809430493874	22943/25928	2
WP2572	Primary focal segmental glomerulosclerosis (FSGS)	5/185	65/5963	0.0503160792778624	0.855158332302239	0.854809430493874	816/22943/84623/4868/5329	5
WP4698	Vitamin D-sensitive calcium signaling in depression	3/185	29/5963	0.0594819007031298	0.855158332302239	0.854809430493874	793/2904/3786	3
WP3958	GPR40 pathway	2/185	13/5963	0.0596622092303888	0.855158332302239	0.854809430493874	5333/113026	2
WP4723	Omega-3 / omega-6 fatty acid synthesis	2/185	13/5963	0.0596622092303888	0.855158332302239	0.854809430493874	9415/5322	2
WP4724	Omega-9 fatty acid synthesis	2/185	13/5963	0.0596622092303888	0.855158332302239	0.854809430493874	79071/9415	2
WP3971	OSX and miRNAs in tooth development	2/185	14/5963	0.0682212405899391	0.896243249082447	0.895877584762136	655/22943	2
WP5115	Network map of SARS-CoV-2 signaling pathway	10/185	190/5963	0.0704360289421452	0.896243249082447	0.895877584762136	9332/3577/1958/3043/10410/7850/6288/6289/5104/7018	10
WP3624	Lung fibrosis	4/185	52/5963	0.0767325944849522	0.896243249082447	0.895877584762136	655/2246/727897/729238	4
WP5053	Development of ureteric collection system	4/185	53/5963	0.0810815589437433	0.896243249082447	0.895877584762136	655/168667/9620/3237	4
WP247	Small ligand GPCRs	2/185	16/5963	0.0864326300525646	0.896243249082447	0.895877584762136	9294/1903	2
WP5149	Lipid metabolism in senescent cells	2/185	18/5963	0.105901441179973	0.896243249082447	0.895877584762136	8399/5322	2
WP117	GPCRs, other	3/185	37/5963	0.105994960746929	0.896243249082447	0.895877584762136	9620/3577/2918	3
WP43	Oxidation by cytochrome P450	3/185	38/5963	0.112586132560141	0.896243249082447	0.895877584762136	1543/1591/339761	3
WP383	Striated muscle contraction pathway	2/185	21/5963	0.136987768435601	0.896243249082447	0.895877584762136	7134/7273	2
WP2865	IL1 and megakaryocytes in obesity	2/185	23/5963	0.158686348860813	0.896243249082447	0.895877584762136	6280/8991	2
WP3658	Wnt/beta-catenin signaling pathway in leukemia	2/185	23/5963	0.158686348860813	0.896243249082447	0.895877584762136	22943/7704	2
WP4341	Non-genomic actions of 1,25 dihydroxyvitamin D3	4/185	68/5963	0.159478258343745	0.896243249082447	0.895877584762136	816/820/1591/5333	4
WP129	Matrix metalloproteinases	2/185	24/5963	0.169763074962941	0.896243249082447	0.895877584762136	4326/4314	2
WP26	S1P receptor signal transduction	2/185	24/5963	0.169763074962941	0.896243249082447	0.895877584762136	9294/1903	2
WP5205	CLOCKED CONTROLLED AUTOPHAGY IN BONE METABOLISM	4/185	71/5963	0.177690454714444	0.896243249082447	0.895877584762136	79365/22943/5187/8600	4
WP4900	Purinergic signaling	2/185	25/5963	0.180965248148679	0.896243249082447	0.895877584762136	136/286530	2
WP176	Folate metabolism	3/185	48/5963	0.185832421673611	0.896243249082447	0.895877584762136	3043/6288/6289	3
WP558	Complement and coagulation cascades	3/185	48/5963	0.185832421673611	0.896243249082447	0.895877584762136	1191/5329/5104	3
WP241	One-carbon metabolism	2/185	26/5963	0.192274560116079	0.896243249082447	0.895877584762136	23382/10840	2
WP299	Nuclear receptors in lipid metabolism and toxicity	2/185	26/5963	0.192274560116079	0.896243249082447	0.895877584762136	8647/1591	2
WP4875	Disruption of postsynaptic signaling by CNV	2/185	26/5963	0.192274560116079	0.896243249082447	0.895877584762136	816/2904	2
WP2806	Complement system	4/185	75/5963	0.202995869661972	0.896243249082447	0.895877584762136	2214/5329/729238/11326	4
WP5113	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway	2/185	27/5963	0.203673706537308	0.896243249082447	0.895877584762136	4314/27035	2
WP706	Sudden infant death syndrome (SIDS) susceptibility pathways	6/185	128/5963	0.20601792868331	0.896243249082447	0.895877584762136	1958/9734/3359/5452/7018/11076	6
WP2882	Nuclear receptors meta-pathway	11/185	268/5963	0.209371871342857	0.896243249082447	0.895877584762136	8647/1543/1958/9982/55554/81706/9588/6286/6513/160728/11254	11
WP4481	Resistin as a regulator of inflammation	2/185	28/5963	0.215146342945897	0.896243249082447	0.895877584762136	5333/113026	2
WP408	Oxidative stress response	2/185	29/5963	0.226677042371287	0.896243249082447	0.895877584762136	1543/27035	2
WP2406	Cardiac progenitor differentiation	2/185	31/5963	0.249855267390055	0.896243249082447	0.895877584762136	22943/55897	2
WP3584	MECP2 and associated Rett syndrome	3/185	56/5963	0.251166507393432	0.896243249082447	0.895877584762136	604/2893/54715	3
WP4018	Clear cell renal cell carcinoma pathways	4/185	83/5963	0.256389181984683	0.896243249082447	0.895877584762136	79365/3099/197257/6513	4
WP3298	Melatonin metabolism and effects	2/185	32/5963	0.261476168410047	0.896243249082447	0.895877584762136	1543/5187	2
WP4823	Genes controlling nephrogenesis	2/185	32/5963	0.261476168410047	0.896243249082447	0.895877584762136	3237/4868	2
WP2007	Iron metabolism in placenta	1/185	10/5963	0.27050514734944	0.896243249082447	0.895877584762136	7018	1
WP4259	Disorders of folate metabolism and transport	1/185	10/5963	0.27050514734944	0.896243249082447	0.895877584762136	10840	1
WP4389	Bile acids synthesis and enterohepatic circulation 	1/185	10/5963	0.27050514734944	0.896243249082447	0.895877584762136	8647	1
WP15	Selenium micronutrient network	3/185	59/5963	0.276524821010541	0.896243249082447	0.895877584762136	3043/6288/6289	3
WP4008	NO/cGMP/PKG mediated neuroprotection	2/185	34/5963	0.284720773290595	0.896243249082447	0.895877584762136	816/2904	2
WP2884	NRF2 pathway	5/185	116/5963	0.291274922651678	0.896243249082447	0.895877584762136	1958/9588/6513/160728/11254	5
WP4271	Vitamin B12 disorders	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	6947	1
WP4553	FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	604	1
WP4629	Aerobic glycolysis	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	6513	1
WP4788	Autosomal recessive osteopetrosis pathways	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	8600	1
WP5052	Nephrogenesis	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	655	1
WP5191	ResolvinE1 and ResolvinD1 signaling pathways promoting inflammation resolution	1/185	11/5963	0.29317548965422	0.896243249082447	0.895877584762136	2358	1
WP5130	Th17 cell differentiation pathway	3/185	62/5963	0.302126739596243	0.896243249082447	0.895877584762136	50615/9572/5187	3
WP2447	Amyotrophic lateral sclerosis (ALS)	2/185	36/5963	0.307896444394593	0.896243249082447	0.895877584762136	4741/6506	2
WP2023	Cell differentiation - expanded index	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	10637	1
WP2881	Estrogen receptor pathway	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	1543	1
WP3876	BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	22943	1
WP4211	Transcriptional cascade regulating adipogenesis	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	10365	1
WP5110	Familial hyperlipidemia type 3	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	7436	1
WP5173	Disorders of galactose metabolism 	1/185	12/5963	0.315145001484524	0.896243249082447	0.895877584762136	5836	1
WP4148	Splicing factor NOVA regulated synaptic proteins	2/185	37/5963	0.319433672031602	0.896243249082447	0.895877584762136	1946/2904	2
WP4754	IL-18 signaling pathway	9/185	239/5963	0.323319278785357	0.896243249082447	0.895877584762136	2904/8870/81618/10365/4314/27035/7018/7052/8600	9
WP2880	Glucocorticoid receptor pathway	3/185	65/5963	0.327842057634911	0.896243249082447	0.895877584762136	9982/81706/6286	3
WP5218	Extrafollicular B cell activation by SARS-CoV-2	3/185	65/5963	0.327842057634911	0.896243249082447	0.895877584762136	57379/60468/604	3
WP2857	Mesodermal commitment pathway	5/185	122/5963	0.32805287609401	0.896243249082447	0.895877584762136	655/1466/22943/8325/10637	5
WP500	Glycogen synthesis and degradation	2/185	38/5963	0.330925202002239	0.896243249082447	0.895877584762136	3099/5836	2
WP185	Integrin-mediated cell adhesion	4/185	94/5963	0.33349808580045	0.896243249082447	0.895877584762136	11131/827/3681/84665	4
WP2289	Drug induction of bile acid pathway	1/185	13/5963	0.336435234172368	0.896243249082447	0.895877584762136	8647	1
WP3301	MFAP5-mediated ovarian cancer cell motility and invasiveness	1/185	13/5963	0.336435234172368	0.896243249082447	0.895877584762136	7134	1
WP5176	Disorders of bile acid synthesis and biliary transport	1/185	13/5963	0.336435234172368	0.896243249082447	0.895877584762136	8647	1
WP5192	Modulation of the PI3K-Akt-mTOR signaling by bioactive sphingolipids	1/185	13/5963	0.336435234172368	0.896243249082447	0.895877584762136	1903	1
WP3937	Microglia pathogen phagocytosis pathway	2/185	39/5963	0.34236279294065	0.896243249082447	0.895877584762136	54210/54209	2
WP5097	CCL18 signaling pathway	2/185	39/5963	0.34236279294065	0.896243249082447	0.895877584762136	6513/7004	2
WP534	Glycolysis and gluconeogenesis	2/185	39/5963	0.34236279294065	0.896243249082447	0.895877584762136	3099/6513	2
WP536	Calcium regulation in cardiac cells	5/185	125/5963	0.346635339924367	0.896243249082447	0.895877584762136	782/816/2707/5569/8787	5
WP4222	Phosphodiesterases in neuronal function	2/185	40/5963	0.353738753233834	0.896243249082447	0.895877584762136	2904/5145	2
WP4312	Rett syndrome causing genes	2/185	40/5963	0.353738753233834	0.896243249082447	0.895877584762136	2904/6334	2
WP12	Osteoclast signaling	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	8600	1
WP2879	Farnesoid X receptor pathway	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	8647	1
WP3969	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	1466	1
WP4584	Biomarkers for pyrimidine metabolism disorders	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	1152	1
WP58	Monoamine GPCRs	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	3357	1
WP697	Estrogen metabolism	1/185	14/5963	0.357067079832555	0.896243249082447	0.895877584762136	1543	1
WP3594	Circadian rhythm genes	6/185	159/5963	0.37182107744001	0.896243249082447	0.895877584762136	79365/1958/4887/9572/5187/60675	6
WP4673	Male infertility	4/185	100/5963	0.376190476797923	0.896243249082447	0.895877584762136	1191/1543/8787/128153	4
WP1946	Cori cycle	1/185	15/5963	0.377060791419541	0.896243249082447	0.895877584762136	6513	1
WP4522	Metabolic pathway of LDL, HDL and TG, including diseases	1/185	15/5963	0.377060791419541	0.896243249082447	0.895877584762136	255738	1
WP5109	Familial hyperlipidemia type 2	1/185	15/5963	0.377060791419541	0.896243249082447	0.895877584762136	255738	1
WP4539	Synaptic signaling pathways associated with autism spectrum disorder	2/185	43/5963	0.387427644687623	0.896243249082447	0.895877584762136	816/2904	2
WP5095	Overview of proinflammatory and profibrotic mediators	3/185	73/5963	0.396094327449915	0.896243249082447	0.895877584762136	6369/29949/4314	3
WP3664	Regulation of Wnt / B-catenin signaling by small molecule compounds	1/185	16/5963	0.396436002177339	0.896243249082447	0.895877584762136	8325	1
WP4478	LTF danger signal response pathway	1/185	16/5963	0.396436002177339	0.896243249082447	0.895877584762136	54210	1
WP410	Exercise-induced circadian regulation	2/185	44/5963	0.398490278158588	0.896243249082447	0.895877584762136	5187/10381	2
WP4971	Phosphoinositides metabolism	2/185	44/5963	0.398490278158588	0.896243249082447	0.895877584762136	5333/113026	2
WP4538	Regulatory circuits of the STAT3 signaling pathway	3/185	75/5963	0.412922022322146	0.896243249082447	0.895877584762136	1844/53832/50615	3
WP3287	Overview of nanoparticle effects	1/185	17/5963	0.415211744500728	0.896243249082447	0.895877584762136	3681	1
WP3967	miR-509-3p alteration of YAP1/ECM axis	1/185	17/5963	0.415211744500728	0.896243249082447	0.895877584762136	7004	1
WP4790	FGF23 signaling in hypophosphatemic rickets and related disorders	1/185	17/5963	0.415211744500728	0.896243249082447	0.895877584762136	1591	1
WP5074	Kallmann syndrome	1/185	17/5963	0.415211744500728	0.896243249082447	0.895877584762136	60675	1
WP691	Tamoxifen metabolism	1/185	17/5963	0.415211744500728	0.896243249082447	0.895877584762136	1543	1
WP2849	Hematopoietic stem cell differentiation	2/185	46/5963	0.420332510822752	0.896243249082447	0.895877584762136	2354/23650	2
WP4533	Transcription co-factors SKI and SKIL protein partners	1/185	18/5963	0.433406468225478	0.896243249082447	0.895877584762136	7004	1
WP4760	PKC-gamma calcium signaling pathway in ataxia	1/185	18/5963	0.433406468225478	0.896243249082447	0.895877584762136	2893	1
WP497	Urea cycle and metabolism of amino groups	1/185	18/5963	0.433406468225478	0.896243249082447	0.895877584762136	1152	1
WP734	Serotonin receptor 4/6/7 and NR3C signaling	1/185	18/5963	0.433406468225478	0.896243249082447	0.895877584762136	1958	1
WP3646	Hepatitis C and hepatocellular carcinoma	2/185	48/5963	0.441766623885573	0.896243249082447	0.895877584762136	3577/7345	2
WP2895	Differentiation of white and brown adipocyte	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	655	1
WP325	Triacylglyceride synthesis	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	56895	1
WP4142	Metabolism of spingolipids in ER and Golgi apparatus	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	8708	1
WP4206	Hereditary leiomyomatosis and renal cell carcinoma pathway	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	6513	1
WP4722	Glycerolipids and glycerophospholipids	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	56895	1
WP732	Serotonin receptor 2 and ELK-SRF/GATA4 signaling	1/185	19/5963	0.451038058364803	0.896243249082447	0.895877584762136	3357	1
WP560	TGF-beta receptor signaling	2/185	50/5963	0.462760866244931	0.896243249082447	0.895877584762136	25805/10637	2
WP167	Eicosanoid synthesis	1/185	20/5963	0.468123852308698	0.896243249082447	0.895877584762136	5322	1
WP2878	PPAR-alpha pathway	1/185	20/5963	0.468123852308698	0.896243249082447	0.895877584762136	55554	1
WP5044	Kynurenine pathway and links to cell senescence	1/185	20/5963	0.468123852308698	0.896243249082447	0.895877584762136	7850	1
WP673	ErbB signaling pathway	3/185	83/5963	0.478553068289567	0.896243249082447	0.895877584762136	816/2069/145957	3
WP4141	PI3K/AKT/mTOR - vitamin D3 signaling	1/185	21/5963	0.484680656502353	0.896243249082447	0.895877584762136	1591	1
WP1772	Apoptosis modulation and signaling	3/185	84/5963	0.486526675143719	0.896243249082447	0.895877584762136	638/8739/7850	3
WP3591	Sleep regulation	1/185	22/5963	0.500724762619328	0.896243249082447	0.895877584762136	4887	1
WP4537	Hippo-Yap signaling pathway	1/185	22/5963	0.500724762619328	0.896243249082447	0.895877584762136	7004	1
WP712	Estrogen signaling pathway	1/185	22/5963	0.500724762619328	0.896243249082447	0.895877584762136	2852	1
WP3942	PPAR signaling pathway	2/185	54/5963	0.503328982086992	0.896243249082447	0.895877584762136	9415/28965	2
WP4816	TGF-beta receptor signaling in skeletal dysplasias	2/185	54/5963	0.503328982086992	0.896243249082447	0.895877584762136	25805/10637	2
WP2858	Ectoderm differentiation	4/185	120/5963	0.514483076655287	0.896243249082447	0.895877584762136	1496/8325/5452/7704	4
WP2361	Gastric cancer network 1	1/185	23/5963	0.516271963244715	0.896243249082447	0.895877584762136	6286	1
WP34	Ovarian infertility	1/185	23/5963	0.516271963244715	0.896243249082447	0.895877584762136	1958	1
WP3893	Development and heterogeneity of the ILC family	1/185	23/5963	0.516271963244715	0.896243249082447	0.895877584762136	7704	1
WP5046	NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence	1/185	23/5963	0.516271963244715	0.896243249082447	0.895877584762136	6513	1
WP4721	Eicosanoid metabolism via lipooxygenases (LOX)	1/185	24/5963	0.531337567083053	0.896243249082447	0.895877584762136	2358	1
WP5183	SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction	1/185	24/5963	0.531337567083053	0.896243249082447	0.895877584762136	27035	1
WP3931	Embryonic stem cell pluripotency pathways	3/185	91/5963	0.540609435129226	0.896243249082447	0.895877584762136	2246/2256/8325	3
WP3680	Physico-chemical features and toxicity-associated pathways	2/185	58/5963	0.541880729097482	0.896243249082447	0.895877584762136	8325/4741	2
WP3613	Photodynamic therapy-induced unfolded protein response	1/185	25/5963	0.545936413705318	0.896243249082447	0.895877584762136	121506	1
WP4969	RAS and bradykinin pathways in COVID-19	1/185	25/5963	0.545936413705318	0.896243249082447	0.895877584762136	1591	1
WP5092	Interactions of natural killer cells in pancreatic cancer	1/185	25/5963	0.545936413705318	0.896243249082447	0.895877584762136	2214	1
WP702	Metapathway biotransformation Phase I and II	4/185	125/5963	0.546977502212588	0.896243249082447	0.895877584762136	1543/1591/339761/64090	4
WP231	TNF-alpha signaling pathway	3/185	92/5963	0.548069158339622	0.896243249082447	0.895877584762136	27035/124056/5836	3
WP183	Proteasome degradation	2/185	59/5963	0.551191462714567	0.896243249082447	0.895877584762136	3135/7345	2
WP4963	p53 transcriptional gene network	2/185	59/5963	0.551191462714567	0.896243249082447	0.895877584762136	136/6513	2
WP5055	Burn wound healing	3/185	93/5963	0.5554582641358	0.896243249082447	0.895877584762136	4314/6280/8796	3
WP5090	Complement system in neuronal development and plasticity	3/185	93/5963	0.5554582641358	0.896243249082447	0.895877584762136	1191/78989/286204	3
WP2817	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4)	1/185	26/5963	0.560082887848888	0.896243249082447	0.895877584762136	8600	1
WP4719	Eicosanoid metabolism via cyclooxygenases (COX)	1/185	26/5963	0.560082887848888	0.896243249082447	0.895877584762136	5322	1
WP2118	Arrhythmogenic right ventricular cardiomyopathy	2/185	60/5963	0.560369155553956	0.896243249082447	0.895877584762136	782/1496	2
WP4155	Endometrial cancer	2/185	61/5963	0.569413060785936	0.896243249082447	0.895877584762136	1496/2246	2
WP4313	Ferroptosis	2/185	61/5963	0.569413060785936	0.896243249082447	0.895877584762136	27035/7018	2
WP2197	Endothelin pathways	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	4886	1
WP2525	Trans-sulfuration and one-carbon metabolism	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	23382	1
WP3869	Cannabinoid receptor signaling	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	1543	1
WP3996	Ethanol effects on histone modifications	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	9734	1
WP5102	Familial partial lipodystrophy (FPLD)	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	10365	1
WP5121	Sphingolipid metabolism in senescence	1/185	27/5963	0.573790933283949	0.896243249082447	0.895877584762136	9294	1
WP289	Myometrial relaxation and contraction pathways	4/185	131/5963	0.584445846345953	0.896243249082447	0.895877584762136	816/5569/5333/8787	4
WP4150	Wnt signaling in kidney disease	1/185	28/5963	0.587074066259432	0.896243249082447	0.895877584762136	8325	1
WP4561	Cell migration and invasion through p75NTR	1/185	28/5963	0.587074066259432	0.896243249082447	0.895877584762136	1946	1
WP4786	Type I collagen synthesis in the context of osteogenesis imperfecta	1/185	28/5963	0.587074066259432	0.896243249082447	0.895877584762136	8600	1
WP4838	Regucalcin in proximal tubule epithelial kidney cells	1/185	28/5963	0.587074066259432	0.896243249082447	0.895877584762136	8600	1
WP5038	Mitochondrial immune response to SARS-CoV-2	1/185	28/5963	0.587074066259432	0.896243249082447	0.895877584762136	27035	1
WP428	Wnt signaling	3/185	98/5963	0.59130819122388	0.897397137269183	0.897031002166258	816/22943/8325	3
WP2374	Oncostatin M signaling pathway	2/185	64/5963	0.595737122127115	0.898229491888896	0.897863017188003	1958/4314	2
WP2380	Brain-derived neurotrophic factor (BDNF) signaling pathway	4/185	134/5963	0.602502623046369	0.898229491888896	0.897863017188003	1958/2904/84894/10603	4
WP4549	Fragile X syndrome	3/185	101/5963	0.611911332961471	0.898229491888896	0.897863017188003	816/54869/2904	3
WP2839	Hair follicle development: organogenesis - part 2 of 3	1/185	30/5963	0.612417600054446	0.898229491888896	0.897863017188003	2246	1
WP4149	White fat cell differentiation	1/185	30/5963	0.612417600054446	0.898229491888896	0.897863017188003	10365	1
WP2636	Common pathways underlying drug addiction	1/185	31/5963	0.624503011143259	0.898229491888896	0.897863017188003	2893	1
WP3414	Initiation of transcription and translation elongation at the HIV-1 LTR	1/185	31/5963	0.624503011143259	0.898229491888896	0.897863017188003	9734	1
WP4241	Type 2 papillary renal cell carcinoma	1/185	31/5963	0.624503011143259	0.898229491888896	0.897863017188003	6513	1
WP2064	Neural crest differentiation	2/185	68/5963	0.628945582908207	0.898229491888896	0.897863017188003	655/9734	2
WP3995	Prion disease pathway	1/185	32/5963	0.636213554457233	0.898229491888896	0.897863017188003	5452	1
WP3998	Prader-Willi and Angelman syndrome	1/185	32/5963	0.636213554457233	0.898229491888896	0.897863017188003	4948	1
WP4542	Leukocyte-intrinsic Hippo pathway functions	1/185	32/5963	0.636213554457233	0.898229491888896	0.897863017188003	7004	1
WP382	MAPK signaling pathway	6/185	210/5963	0.640543012608224	0.898229491888896	0.897863017188003	782/1844/2246/2256/7850/25780	6
WP3617	Photodynamic therapy-induced NF-kB survival signaling	1/185	33/5963	0.647560796478041	0.898229491888896	0.897863017188003	4314	1
WP465	Tryptophan metabolism	1/185	33/5963	0.647560796478041	0.898229491888896	0.897863017188003	1543	1
WP4756	Renin-angiotensin-aldosterone system (RAAS)	1/185	33/5963	0.647560796478041	0.898229491888896	0.897863017188003	816	1
WP619	Type II interferon signaling	1/185	34/5963	0.658555948695843	0.899074588770212	0.898707769272549	2633	1
WP716	Vitamin A and carotenoid metabolism	1/185	34/5963	0.658555948695843	0.899074588770212	0.898707769272549	195814	1
WP4336	ncRNAs involved in Wnt signaling in hepatocellular carcinoma	2/185	72/5963	0.66000727058788	0.899074588770212	0.898707769272549	22943/8325	2
WP2371	Parkinson's disease pathway	1/185	35/5963	0.669209878446436	0.899074588770212	0.898707769272549	7345	1
WP3614	Photodynamic therapy-induced HIF-1 survival signaling	1/185	35/5963	0.669209878446436	0.899074588770212	0.898707769272549	6513	1
WP5198	Inflammatory bowel disease signaling	1/185	35/5963	0.669209878446436	0.899074588770212	0.898707769272549	50615	1
WP2873	Aryl hydrocarbon receptor pathway	1/185	36/5963	0.679533119419346	0.899074588770212	0.898707769272549	1543	1
WP3850	Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling	1/185	36/5963	0.679533119419346	0.899074588770212	0.898707769272549	84676	1
WP4877	Host-pathogen interaction of human coronaviruses - MAPK signaling	1/185	36/5963	0.679533119419346	0.899074588770212	0.898707769272549	10410	1
WP4331	Neovascularisation processes	1/185	37/5963	0.689535881846783	0.907654375084031	0.907284055061557	94	1
WP4758	Nephrotic syndrome	1/185	38/5963	0.699228062383122	0.915597311803994	0.915223751089264	4868	1
WP4258	lncRNA in canonical Wnt signaling and colorectal cancer	2/185	78/5963	0.702667704407716	0.915597311803994	0.915223751089264	22943/8325	2
WP5124	Alzheimer's disease	6/185	226/5963	0.709734393963223	0.920158159007596	0.919782737482093	22943/8325/2904/3800/27035/10381	6
WP2853	Endoderm differentiation	3/185	118/5963	0.715231774806724	0.922648989500674	0.92227255172446	655/22943/1844	3
WP2059	Alzheimer's disease and miRNA effects	6/185	229/5963	0.721652865042234	0.926300692442271	0.925922764783176	22943/8325/2904/3800/27035/10381	6
WP4290	Metabolic reprogramming in colon cancer	1/185	41/5963	0.726535574659199	0.926480629591716	0.926102628518851	6513	1
WP2036	TNF-related weak inducer of apoptosis (TWEAK) signaling pathway	1/185	42/5963	0.735078451843942	0.926480629591716	0.926102628518851	84676	1
WP4534	Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms	1/185	42/5963	0.735078451843942	0.926480629591716	0.926102628518851	7004	1
WP4223	Ras signaling	4/185	161/5963	0.742497074306518	0.926480629591716	0.926102628518851	2904/8399/5322/25780	4
WP2586	Aryl hydrocarbon receptor pathway	1/185	43/5963	0.743355852014331	0.926480629591716	0.926102628518851	1543	1
WP2038	Microtubule cytoskeleton regulation	1/185	44/5963	0.751375981638883	0.926480629591716	0.926102628518851	11076	1
WP2267	Synaptic vesicle pathway	1/185	44/5963	0.751375981638883	0.926480629591716	0.926102628518851	23025	1
WP4861	Endoplasmic reticulum stress response in coronavirus infection	1/185	44/5963	0.751375981638883	0.926480629591716	0.926102628518851	81706	1
WP5087	Malignant pleural mesothelioma	10/185	381/5963	0.75411214036535	0.926480629591716	0.926102628518851	1496/22943/1825/1946/2246/2256/8325/4314/6513/7004	10
WP4718	Cholesterol metabolism with Bloch and Kandutsch-Russell pathways	1/185	45/5963	0.759146794850035	0.928245843939853	0.927867122665295	9415	1
WP4262	Breast cancer pathway	3/185	129/5963	0.769995137300436	0.937069553884492	0.936687232565078	2246/8325/8600	3
WP2272	Pathogenic Escherichia coli infection	1/185	49/5963	0.787887560115663	0.949636225051951	0.949248776571718	10381	1
WP4239	Epithelial to mesenchymal transition in colorectal cancer	3/185	134/5963	0.791912403026461	0.949636225051951	0.949248776571718	8999/9073/8325	3
WP3286	Copper homeostasis	1/185	51/5963	0.80095156288384	0.949636225051951	0.949248776571718	79689	1
WP23	B cell receptor signaling pathway	2/185	96/5963	0.804697815565143	0.949636225051951	0.949248776571718	604/25780	2
WP2864	Apoptosis-related network due to altered Notch3 in ovarian cancer	1/185	52/5963	0.80718024367993	0.949636225051951	0.949248776571718	8870	1
WP4906	3q29 copy number variation syndrome	1/185	52/5963	0.80718024367993	0.949636225051951	0.949248776571718	7018	1
WP2795	Cardiac hypertrophic response	1/185	53/5963	0.813215035579645	0.949636225051951	0.949248776571718	9734	1
WP2431	Spinal cord injury	2/185	98/5963	0.81388032440252	0.949636225051951	0.949248776571718	1958/5322	2
WP4787	Osteoblast differentiation and related diseases	2/185	98/5963	0.81388032440252	0.949636225051951	0.949248776571718	2246/8325	2
WP2018	RANKL/RANK signaling pathway	1/185	54/5963	0.819061942249318	0.949636225051951	0.949248776571718	8600	1
WP3888	VEGFA-VEGFR2 signaling pathway	10/185	409/5963	0.82625767656435	0.949636225051951	0.949248776571718	1466/22943/1958/10755/9734/3748/5322/5329/9588/7004	10
WP4541	Hippo-Merlin signaling dysregulation	2/185	101/5963	0.826935282225903	0.949636225051951	0.949248776571718	3681/7004	2
WP710	DNA damage response (only ATM dependent)	2/185	103/5963	0.835177613668009	0.949636225051951	0.949248776571718	604/638	2
WP474	Endochondral ossification	1/185	57/5963	0.835532647623228	0.949636225051951	0.949248776571718	655	1
WP4808	Endochondral ossification with skeletal dysplasias	1/185	57/5963	0.835532647623228	0.949636225051951	0.949248776571718	655	1
WP3651	Pathways affected in adenoid cystic carcinoma	1/185	58/5963	0.84068443566754	0.95130080878169	0.950912681156728	4603	1
WP304	Kit receptor signaling pathway	1/185	59/5963	0.845675693821901	0.952769995659609	0.952381268611197	10603	1
WP4659	Gastrin signaling pathway	2/185	108/5963	0.854260042922939	0.958256917713558	0.957865952018856	1958/3067	2
WP2359	Parkin-ubiquitin proteasomal system pathway	1/185	62/5963	0.859735284330477	0.960223824057416	0.959832055871346	10381	1
WP2032	Thyroid stimulating hormone (TSH) signaling pathway	1/185	64/5963	0.868392916716404	0.961940491961935	0.961548023380963	1958	1
WP481	Insulin signaling	3/185	156/5963	0.868729203981127	0.961940491961935	0.961548023380963	1958/10603/6513	3
WP1982	Sterol regulatory element-binding proteins (SREBP) signaling	1/185	66/5963	0.876518879995622	0.966418252302865	0.96602395681029	820	1
WP4949	16p11.2 proximal deletion syndrome	1/185	67/5963	0.880392715369678	0.966558810916498	0.966164458076467	23025	1
WP4656	Joubert syndrome	1/185	71/5963	0.894716079166647	0.969877994665629	0.969482287609462	5145	1
WP4217	Ebola virus infection in host	2/185	124/5963	0.902591000033466	0.969877994665629	0.969482287609462	26762/3135	2
WP51	Regulation of actin cytoskeleton	2/185	127/5963	0.909805930077097	0.969877994665629	0.969482287609462	2246/2256	2
WP2328	Allograft rejection	1/185	76/5963	0.910243932674537	0.969877994665629	0.969482287609462	3135	1
WP4016	DNA IR-damage and cellular response via ATR	1/185	76/5963	0.910243932674537	0.969877994665629	0.969482287609462	604	1
WP3925	Amino acid metabolism	1/185	77/5963	0.913064532717889	0.969877994665629	0.969482287609462	3067	1
WP2355	Corticotropin-releasing hormone signaling pathway	1/185	78/5963	0.915796959059579	0.969877994665629	0.969482287609462	2354	1
WP4022	Pyrimidine metabolism	1/185	79/5963	0.918443953549635	0.969877994665629	0.969482287609462	956	1
WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	5/185	265/5963	0.920476694874842	0.969877994665629	0.969482287609462	1946/2246/2256/3681/6513	5
WP1544	MicroRNAs in cardiomyocyte hypertrophy	1/185	80/5963	0.921008173228989	0.969877994665629	0.969482287609462	9734	1
WP254	Apoptosis	1/185	84/5963	0.930487620243546	0.97070849132059	0.970312445424498	8739	1
WP4540	Hippo signaling regulation pathways	1/185	84/5963	0.930487620243546	0.97070849132059	0.970312445424498	7004	1
WP69	T-cell receptor signaling pathway	1/185	86/5963	0.934793969687693	0.97070849132059	0.970312445424498	3604	1
WP399	Wnt signaling pathway and pluripotency	1/185	87/5963	0.936846567204756	0.97070849132059	0.970312445424498	8325	1
WP4657	22q11.2 copy number variation syndrome	1/185	90/5963	0.942626658071421	0.972790711129707	0.972393815694729	150209	1
WP4658	Small cell lung cancer	1/185	93/5963	0.94788032595861	0.974315235447495	0.973917718011572	22798	1
WP4172	PI3K-Akt signaling pathway	4/185	280/5963	0.97750881953063	0.99722743117034	0.996820565633347	1946/2246/2256/22798	4
WP3915	Angiopoietin-like protein 8 regulatory pathway	1/185	125/5963	0.981346560537445	0.99722743117034	0.996820565633347	6513	1
WP366	TGF-beta signaling pathway	1/185	130/5963	0.984121515911548	0.99722743117034	0.996820565633347	2354	1
WP4396	Nonalcoholic fatty liver disease	1/185	137/5963	0.98732999556881	0.99722743117034	0.996820565633347	125965	1
WP3929	Chemokine signaling pathway	1/185	152/5963	0.992196239563372	0.99722743117034	0.996820565633347	6369	1
WP437	EGF/EGFR signaling pathway	1/185	157/5963	0.993362208568905	0.99722743117034	0.996820565633347	2354	1
WP4352	Ciliary landscape	1/185	201/5963	0.998411851361729	0.998411851361729	0.998004502585164	4741	1
